Gapping down
In reaction to earnings/guidance:
- CHWY -1%
Other news:
- VRTX -13.7% (releases data from Phase 2 study of VX-864)
- CRIS -12.8% (reports updated data from ongoing Phase 1/2 study of CA-4948 Monotherapy)
- ELY -4.1% (to be added to S&P MidCap 400)
- SNOW -3.5% (hosting Investor Day today)
- INCY -3.1% (announces that the U.S. Food and Drug Administration has extended the review period for the New Drug Application for ruxolitinib cream for the treatment of atopic dermatitis)
- AGNC -3% (reports tangible net book value of $16.82/sh)
- ADC -3% (prices offering of 4 mln shares of common stock for gross proceeds of $286 mln)
- LTHM -2.1% (prices offering of 13 mln shares of common stock at $17.50 per share)
- REVG -1.6% (prices offering of 5.5 mln shares of common stock by selling shareholders at $15.50 per share)
- EGLX -1.6% (priced 8 mln share offering at $5.75 per common share)
Analyst comments:
- LOGI -1.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- CRCT -1.5% (downgraded to Equal-Weight from Overweight at Morgan Stanley)